Quest Diagnostics Sees 9.7% FY2025 Earnings Growth; Consensus Raised to $9.80
Quest Diagnostics holds a Zacks #2 (Buy) rank with top-tier VGM Score of A and Growth Score of B, forecasting 9.7% year-over-year earnings growth for fiscal 2025. The consensus estimate rose $0.01 to $9.80 per share, backed by a +2.5% average earnings surprise and an upward revision by one analyst.
1. Zacks Rank and Style Scores
Quest Diagnostics carries a Zacks Rank #2 (Buy) and excels in Zacks Style Scores with an A-grade VGM (Value, Growth, Momentum) and a B-grade Growth Score, indicating strong combined potential and sustainable earnings momentum.
2. Earnings Forecast and Consensus
The fiscal 2025 earnings estimate for Quest Diagnostics stands at $9.80 per share, up $0.01 in the past 60 days, reflecting a projected 9.7% year-over-year increase backed by improving diagnostic service demand.
3. Analyst Revisions and Surprises
At least one analyst raised their fiscal 2025 estimate in the last two months, while DGX has delivered an average earnings surprise of +2.5%, underscoring consistent outperformance against market expectations.
4. Growth Drivers
Key growth drivers include expanded diagnostic testing for hospitals and independent networks, ongoing adoption of advanced lab services, and strategic focus on cost efficiencies across its Professional Lab Services offerings.